Accretion Pharmaceuticals Share Price | Accretion Pharmaceuticals Stock Screener
ACCPL
Pharmaceuticals
Track Accretion Pharmaceuticals share price live with TickJournal's free stock screener.
Check Accretion Pharmaceuticals yearly highs lows for the annual price range and momentum.
Use the Accretion Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Accretion Pharmaceuticals Market Cap
₹120.05 Cr.
ACCPL P/E Ratio (TTM)
-
Accretion Pharmaceuticals P/B Ratio
2.70
EPS (TTM)
₹8.48
Dividend Yield
-
Debt to Equity
1.33
ACCPL 52 Week High
-
Accretion Pharmaceuticals 52 Week Low
-
Operating Margin
-
Profit Margin
-
ACCPL Revenue (TTM)
-
EBITDA
-
Net Income
-
Total Assets
₹40.00
Total Equity
₹15.00
Accretion Pharmaceuticals Share Price Chart
Screen Accretion Pharmaceuticals share price with an interactive chart. Analyse ACCPL price trends and volatility across different timeframes.
Accretion Pharmaceuticals Company Profile - Fundamental Screener
Screen Accretion Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ACCPL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0T8T01010
Accretion Pharmaceuticals Balance Sheet Screener
Screen ACCPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 |
|---|---|---|
| Assets | ||
| Total Assets | 40 | 27 |
| Current Assets | 34 | 22 |
| Fixed Assets | 6 | 5 |
| Liabilities | ||
| Total Liabilities | 0 | 0 |
| Current Liabilities | 1 | 7 |
| Non-Current Liabilities | 0 | 0 |
| Shareholders' Equity | ||
| Total Equity | 15 | 6 |
| Share Capital | 8 | 4 |
| Reserves & Surplus | 7 | 2 |
Accretion Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Accretion Pharmaceuticals income statement and profit fundamentals.
Analyze ACCPL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Accretion Pharmaceuticals share price evaluation.
| Item | None-None | 2025-March | 2024-March |
|---|---|---|---|
| Revenue | 0 | 58 | 13 |
| Expenses | 0 | 46 | 11 |
| EBITDA | 0 | 12 | 3 |
| Operating Profit % | 0.00% | 21.00% | 19.00% |
| Depreciation | 0 | 1 | 0 |
| Interest | 0 | 1 | 0 |
| Profit Before Tax | 0 | 10 | 2 |
| Tax | 0 | 3 | 1 |
| Net Profit | 0 | 7 | 2 |
| EPS | 0.00 | 8.48 | 1.96 |
Accretion Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen ACCPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March |
|---|---|---|
| Operating Activities | 6 | -12 |
| Investing Activities | -2 | -6 |
| Financing Activities | -4 | 17 |
| Net Cash Flow | 0 | 0 |
Accretion Pharmaceuticals Shareholding Pattern Screener
See Accretion Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Accretion Pharmaceuticals promoter holding and ownership changes for ACCPL on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-May | 2025-Jan | 2024-Sept |
|---|---|---|---|---|---|---|---|
| Promoter Holding | 73.52% | 73.52% | 73.52% | 73.50% | 73.50% | 100.00% | 100.00% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.92% | 22.01% | 22.85% | 21.46% | 19.44% | 0.00% | 0.00% |
| Other Holding | 3.56% | 4.47% | 3.63% | 5.04% | 7.06% | 0.00% | 0.00% |
| Shareholder Count | 1,182 | 1,179 | 1,498 | 1,628 | 8 | 8 | 8 |
Accretion Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Accretion Pharmaceuticals dividend history with payout and yield data.
View Accretion Pharmaceuticals dividend details including ex-dates and amounts for ACCPL stock.
Accretion Pharmaceuticals Stock Index Membership
See which indices include Accretion Pharmaceuticals stock.
Check ACCPL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Accretion Pharmaceuticals Market Events Screener - Corporate Actions
Get Accretion Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Accretion Pharmaceuticals stock events that may affect ACCPL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-08 | 2026-05-08 | Quarterly Result Announcement | NA | 0.69% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 16.56% |
| 2025-06-11 | 2025-06-11 | Quarterly Result Announcement | NA | 5.68% |
Accretion Pharmaceuticals Competitors Screener - Peer Comparison
Screen ACCPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 443,925 | 39.88 | 54,729 | 9.71% | 10,980 | 67.28 |
| Divis Laboratories | 177,917 | 71.25 | 9,712 | 18.67% | 2,191 | 73.20 |
| Torrent Pharmaceuticals | 147,505 | 63.70 | 11,539 | 6.99% | 1,911 | 62.44 |
| Lupin | 111,651 | 22.95 | 22,910 | 13.74% | 3,306 | 68.53 |
| Cipla | 110,214 | 23.76 | 28,410 | 7.12% | 5,291 | 70.25 |
| Dr Reddys Laboratories | 109,422 | 19.21 | 33,741 | 16.73% | 5,725 | 55.92 |
| Mankind Pharma | 97,463 | 53.13 | 12,744 | 20.90% | 2,007 | 74.11 |
| Zydus Life Science | 94,465 | 18.26 | 23,511 | 18.55% | 4,615 | 57.54 |
| Aurobindo Pharma | 86,191 | 23.80 | 32,346 | 9.43% | 3,484 | 71.12 |
| Glenmark Pharmaceuticals | 67,096 | 64.12 | 13,436 | 6.18% | 1,047 | 63.49 |
Accretion Pharmaceuticals Company Announcements - News Screener
Screen ACCPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.